Modified-release hydrocortisone (Plenadren) launched for adrenal insufficiency

Plenadren (hydrocortisone) is indicated for maintenance therapy in adrenal insufficiency.

Modified-release hydrocortisone is not associated with the non-physiological cortisol peaks produced by standard glucocorticoid therapy.
Modified-release hydrocortisone is not associated with the non-physiological cortisol peaks produced by standard glucocorticoid therapy.

Plenadren (hydrocortisone) is a modified-release hydrocortisone tablet given once daily. It is intended to better mimic the physiological pattern of cortisol production than standard glucocorticoid replacement therapy.

Cortisol exposure

In a randomised open-label 12-week crossover study in 64 patients with primary adrenal insufficiency, once-daily modified-release hydrocortisone resulted in increased cortisol exposure during the first four hours after intake in the morning, with reduced exposure in the late afternoon and evening and over the 24-hour period compared with standard-release hydrocortisone (given three times daily). The safety profile was similar to that of conventional hydrocortisone.

View Plenadren drug record
 
Further information: ViroPharma

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Consider bisphosphonates to combat osteoporosis risk in asthma patients taking steroids, say researchers
Medicines shortages increase as prescribing costs rise £158 million

Medicines shortages increase as prescribing costs rise £158 million

Increasing medicines shortages have added more than...